Bio News
Novartis has secured access to RNA technology from China’s Abogen Biosciences in exchange for an upfront payment of $575 million (about 770 billion won).
Abogen is granting Novartis an option to license ABO2203, an mRNA-based next-generation T-cell engager targeting CD3 and CD19.
Abogen confirmed ABO2203’s tolerability in an early-stage clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and could receive up to an additional $7.2 billion upon achievement of milestones.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
